BioCentury | Feb 1, 2019
Clinical News

Orphazyme finds path forward for Niemann-Pick therapy in subgroup data

...at least four years old (p=0.0219) and 2 points in patients who were also receiving miglustat...
BioCentury | Jan 30, 2019
Clinical News

Orphazyme finds path forward for Niemann-Pick therapy in subgroup data

...at least four years old (p=0.0219) and 2 points in patients who were also receiving miglustat...
BioCentury | May 21, 2015
Targets & Mechanisms

Intersection in marrow

...symptoms that accompany both diseases. Suppression of myeloma-related bone erosion by the Gaucher's drug Zavesca miglustat...
...and add a new angle to complement the growing list of myeloma therapies in development. Zavesca...
...in glycosphingolipid synthesis. UCB Group (Euronext:UCB) and Actelion Ltd. (SIX:ATLN) market the GCS inhibitor Zavesca miglustat...
BioCentury | May 4, 2015
Emerging Company Profile

Nixing Niemann-Pick

...removes cholesterol. In animal models, it has slowed disease progression and prolonged survival vs. Zavesca miglustat...
...showed 2-hydroxypropyl-b-cyclodextrin nearly doubled the median life span compared with Zavesca, while the addition of Zavesca...
...reports suggest limited efficacy for miglustat" in NPC. There are no NPC survival data on Zavesca's...
BioCentury | Oct 2, 2014
Strategy

Progressive thinking in MS

...cells Jack van Horssen, Free University Amsterdam, the Netherlands Test whether the glucosyltransferase inhibitor Zavesca miglustat...
BioCentury | Feb 20, 2014
Distillery Techniques

Technology: Assays & screens

...compartment volume and NPC1 disease severity. In B cells from patients with NPC1 receiving Zavesca miglustat...
...testing the assay in patients with other lysosomal storage disorders. Actelion Ltd.'s and UCB Group's Zavesca...
BioCentury | Feb 13, 2014
Targets & Mechanisms

A RIPping target in Gaucher's disease

...Shire plc Vpriv velaglucerase alfa rGCase ERT Marketed Actelion Ltd. (SIX:ATLN); UCB Group (Euronext:UCB) Zavesca miglustat...
BioCentury | Apr 9, 2012
Finance

Highlights of weekly biotech stock moves

...to CHF33.36 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Brazaves miglustat...
BioCentury | Apr 9, 2012
Clinical News

Brazaves miglustat regulatory update

...MHLW) approved Actelion's Brazaves miglustat to treat Niemann-Pick type C disease. Miglustat is marketed as Zavesca...
...the U.S., EU and Canada, to treat Type I Gaucher's disease. Actelion has rights to miglustat...
...Israel. Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland UCB Group (Euronext:UCB), Brussels, Belgium Product: Brazaves miglustat ( OGT 918...
BioCentury | Nov 7, 2011
Emerging Company Profile

Orphazyme: One for all

...fortnight, maybe every week." Hinsby believes Hsp70 provides several benefits over Actelion Ltd. 's Zavesca miglustat...
...85% and 65% of patients in Zavesca's clinical trials had diarrhea and weight loss, respectively. Zavesca...
Items per page:
1 - 10 of 184